1 min read
Add as a preferred source on Google

Instil Bio Posts $0.62 GAAP Loss Per Share, $0.48 Non-GAAP Loss Per Share

Instil Bio expects its $67.1 million in cash, cash equivalents, restricted cash, marketable securities and long-term investments to fund its operating plan through 2027.

An unmarked vial stands beside a glass vessel on a laboratory bench / TokenPost.ai
An unmarked vial stands beside a glass vessel on a laboratory bench / TokenPost.ai

Instil Bio posted a $4.231 million net loss for the quarter ended Sept. 30. It expects its $67.1 million in cash, cash equivalents, restricted cash, marketable securities and long-term investments to fund its operating plan through 2027.

The biotechnology company announced its results Nov. 16 at 7 a.m. ET (12:00 UTC). Its GAAP loss was $0.62 per basic and diluted share, and its non-GAAP loss was $0.48 per share.

Instil Bio’s non-GAAP calculation excludes noncash stock-based compensation, restructuring charges and impairment charges. Instil Bio advances treatment candidates through subsidiaries organized around individual assets, including programs it develops or licenses.

As of Sept. 30, Instil Bio held $67.1 million in cash, cash equivalents, restricted cash, marketable securities and long-term investments. It expects those resources to fund its operating plan through 2027.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…